Zhou Qing, Hou Yilin, Zhang Li, Wang Jianlin, Qiao Youbei, Guo Songyan, Fan Li, Yang Tiehong, Zhu Lin, Wu Hong
Department of Pharmaceutical Analysis, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
Innovation experimental college, Northwest A&F University, Yangling 712100, China.
Theranostics. 2017 Apr 10;7(7):1806-1819. doi: 10.7150/thno.18607. eCollection 2017.
Poly(β-L-malic acid) (PMLA), a natural aliphatic polyester, has been proven to be a promising carrier for anti-cancer drugs. In spite of excellent bio-compatibility, the application of PMLA as the drug carrier for cancer therapy is limited by its low cellular uptake efficiency. The strong negative charge of PMLA impedes its uptake by cancer cells because of the electrostatic repulsion. In this study, a dual pH-sensitive charge-reversal PMLA-based nanocomplex (PMLA-PEI-DOX-TAT@PEG-DMMA) was developed for effective tumor-targeted drug delivery, enhanced cellular uptake, and intracellular drug release. The prepared nanocomplex showed a negative surface charge at the physiological pH, which could protect the nanocomplex from the attack of plasma proteins and recognition by the reticuloendothelial system, so as to prolong its circulation time. While at the tumor extracellular pH 6.8, the DMMA was hydrolyzed, leading to the charge reversal and exposure of the TAT on the polymeric micelles, thus enhancing the cellular internalization. Then, the polymeric micelles underwent dissociation and drug release in response to the acidic pH in the lyso/endosomal compartments of the tumor cell. Both and efficacy studies indicated that the nanocomplex significantly inhibited the tumor growth while the treatment showed negligible systemic toxicity, suggesting that the developed dual pH-sensitive PMLA-based nanocomplex would be a promising drug delivery system for tumor-targeted drug delivery with enhanced anticancer activity.
聚(β-L-苹果酸)(PMLA)是一种天然脂肪族聚酯,已被证明是一种很有前景的抗癌药物载体。尽管具有出色的生物相容性,但PMLA作为癌症治疗药物载体的应用受到其低细胞摄取效率的限制。PMLA的强负电荷由于静电排斥作用阻碍了其被癌细胞摄取。在本研究中,开发了一种基于PMLA的双pH敏感电荷反转纳米复合物(PMLA-PEI-DOX-TAT@PEG-DMMA),用于有效的肿瘤靶向药物递送、增强细胞摄取和细胞内药物释放。制备的纳米复合物在生理pH下表面带负电荷,这可以保护纳米复合物免受血浆蛋白的攻击和网状内皮系统的识别,从而延长其循环时间。而在肿瘤细胞外pH 6.8时,DMMA被水解,导致电荷反转和TAT暴露在聚合物胶束上,从而增强细胞内化。然后,聚合物胶束响应肿瘤细胞溶酶体/内体区室中的酸性pH发生解离和药物释放。体内和体外疗效研究均表明,该纳米复合物显著抑制肿瘤生长,而治疗显示出可忽略不计的全身毒性,这表明所开发的基于PMLA的双pH敏感纳米复合物将是一种有前景的药物递送系统,用于肿瘤靶向药物递送并增强抗癌活性。